General Counsel · Esperion Therapeutics, Inc. (ESPR)

Benjamin Looker

FY2024 is the first fiscal year CompBrief holds for Benjamin Looker as a named executive officer of Esperion Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,130,827

Salary $471,000Stock awards $205,000

5th of 5 named executive officers at Esperion Therapeutics by FY2024 total.

5 named officers on file for Esperion Therapeutics, FY2024

Benjamin Looker’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • ESPR’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Esperion Therapeutics’s whole pay program stands against its peers

  • Esperion Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ESPR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 17, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Benjamin Looker’s full pay file as a PDF — free

More than this page: up to 10 years of Benjamin’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Benjamin Looker compensation by year

Esperion Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Esperion Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$471,000
Bonus$0
Stock awards$205,000
Option awards$229,477
Non-equity incentive$213,750
Pension and deferred compensation$0
All other$11,600
Total$1,130,827

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Esperion Therapeutics, Inc. DEF 14A filed April 17, 2025, accession 0001628280-25-018229, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Esperion Therapeutics, Inc. filed document, accession 0001628280-25-018229. Every figure is read from that document and cited to the page and table it appears in. Filed April 17, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU81,250$178,750—
RSU22,125$48,675—
RSU11,533$25,373—
Option31,392—$3.65
Option48,883—$4.02
Option121,875—$2.05

Per the Outstanding Equity Awards at Fiscal Year-End table in Esperion Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

14 Form 4 lines since the FY2024 proxy (filed April 17, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-07-13Disposition to the issuer derivative—150,000—0
2026-07-13Disposition to the issuer derivative—201,000—0
2026-07-13Disposition to the issuer derivative—269,230—0
2026-07-13Disposition to the issuer—667,524—0
2026-06-17Sale—11,824$3.15667,524
2026-03-17Sale—5,708$2.70679,348
2026-03-13Grant or award derivative—269,230$0.00269,230
2026-03-13Grant or award—300,840$0.00685,056

The 8 most recent of 14 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Esperion Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Sheldon KoenigPresident and Chief Executive Officer$3,175,240
JoAnne FoodyChief Medical Officer$1,870,559
Benjamin HalladayChief Financial Officer$1,368,427
Eric WarrenChief Commercial Officer$1,149,844
Benjamin Looker · this pageGeneral Counsel$1,130,827

The full Esperion Therapeutics compensation record

free company brief

This page is one person within Esperion Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Esperion Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Esperion Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Benjamin Looker's compensation dossier · One-time report. No refunds.